Portsmouth, VA -- (SBWire) -- 04/07/2016 --ResearchPeptides.com, one of the most influential and informative forum sites in the world, discusses the infamous truth behind the cause and possible treatment to Laron syndrome. According to ResearchPeptides.com, Laron syndrome is a type of rare health condition that is the result of the body's inability to make the most out of the growth hormones such as the insulin-like growth factor (IGF-1). The lack of development of growth hormones tends to prevent the body from growing taller. Thus, an individual who experiences Laron syndrome tends to be smaller than the normal height of people in their age.
ResearchPeptides.com reveals that an individual with Laron syndrome is born with a relatively normal height and weight. However, when the individual grows older, the growth hormones show slow development.
Aside from the lack of height, Laron syndrome patients also experience reduced muscle strength and endurance. ResearchPeptides.com also revealed that Laron syndrome patients suffer from a condition called as hypoglycemia or low blood sugar levels. Laron syndrome patients also experience delayed puberty and having small genitals. Aside from that, Laron syndrome patients have thinner hair and it is usually fragile. In addition to that, Laron syndrome patients experience dental abnormalities that worsen their situation.
According to ResearchPeptides.com, there are numerous studies and researches that are being conducted in order to provide a cure for the Laron syndrome patients. In connection with this, endocrinologists Arlan Rosenbloom and Jaime Guevarra-Aguirre collaborated to work and do further research regarding Laron syndrome and its possible impact in the health community. Based on the first few findings of the two, the lack of insulin-like growth factor (IGF-1) from the patients who have Laron syndrome can be the answer to the number one cause of death in the world- cancer. After years of study, Arlan Rosenbloom and Jaime Guevarra-Aguirre are still finding ways to come up with a firm conclusion that Laron syndrome patients can live longer than the average lifespan of individuals who don't have problems with the formation of insulin-like growth factor (IGF-1).
On the other hand, individuals who are not suffering from Laron syndrome opt to use an insulin-like growth factor (IGF-1) medicine known as the IGF 1 DES- the shortest variety of the IGF-1 chain. Aside from that, the IGF 1 DES is proven to be five times more powerful than the other version of the IGF-1 chain.
About Research Peptides
Researchpeptides.com is a blog or a forum website where people can learn and share their views on specific topics and all its other important aspects. Interested people should sign up and create a publicly viewable profile. The forum provides verified topic discussions from all its members for the purpose of research.
Contact:
Dimitry Vital
PR and Marketing @ Research Peptides Forum
Telephone: 757-394-2311
Website: http://www.researchpeptides.com
